168 results about "Abnormal alkaline phosphatase" patented technology

The invention relates to the field of biomedicine, particularly provides a copper-based nano-enzyme as well as a preparation method and application thereof, and aims to solve the problems that in the prior art, clinical treatment on primary sclerosing cholangitis (PSC) is difficult in diagnosis and lacks of effective treatment drugs. The copper-based nano-enzyme comprises a nano-enzyme carrier and a copper-based nano-enzyme, wherein the nano-enzyme carrier is a two-dimensional nanosheet formed by copper ions, gallic acid and ursodesoxycholic acid through coordinate bonds; the probe molecule is a cyanine dye molecule connected to the surface of the nano-enzyme carrier through a covalent bond; wherein the fluorescence intensity of the copper-based nano enzyme is enhanced after the action of the alkaline phosphatase. The three functions of alkaline phosphatase responsive diagnosis, nano-enzyme catalytic treatment and ursodesoxycholic acid hepatic targeting are innovatively and synergistically integrated into one nano platform, the treatment function can be executed while specific imaging diagnosis is performed on diseases, and a new strategy is provided for diagnosis and treatment of diseases such as PSC.

The invention discloses an eggshell membrane peptide for enhancing bone mineral density as well as a preparation method and application thereof, belongs to the technical field of egg by-product processing, and particularly relates to a preparation method of the eggshell membrane peptide for enhancing bone mineral density, which comprises the following steps: carrying out vacuum freeze drying and crushing on an eggshell membrane to obtain eggshell membrane powder; mixing the eggshell membrane powder with deionized water to obtain an eggshell membrane solution; adding keratinase, performing enzymolysis, and taking supernate; adding collagenase, carrying out enzymolysis, and centrifuging to take supernate, so as to obtain primary enzymatic hydrolysate; adding alkaline phosphatase, performing enzymolysis and centrifugation, and taking supernate to obtain enzymatic hydrolysate; and performing ultrafiltration and drying to obtain the eggshell membrane peptide. According to the eggshell membrane peptide for enhancing the bone mineral density, keratin cross-linking is destroyed through enzymolysis of keratinase, active peptide capable of stimulating osteoblast proliferation is released through enzymolysis of collagenase, phosphopeptide calcium binding sites are further activated through enzymolysis of alkaline phosphatase, calcium salt deposition is promoted, and the eggshell membrane peptide for enhancing the bone mineral density is provided.

The invention provides a multicolor visual semi-quantitative detection method for miRNA in skin interstitial fluid, which comprises the following steps: extracting a skin interstitial fluid sample in a minimally invasive manner by combining a microneedle patch with a vacuum negative pressure technology; the method comprises the following steps: incubating a skin interstitial fluid sample and a magnetic nanoprobe of which the surface is immobilized with a hairpin probe H1, opening H1 in the presence of target miRNA, triggering a subsequent hybridization chain reaction of a hairpin probe H2 and H3, and constructing a biotin-rich DNA compound on the surface of a magnetic bead; the method comprises the following steps: carrying out enzyme labeling by using an alkaline phosphatase-streptavidin conjugate, catalyzing ascorbic acid phosphate to generate ascorbic acid to reduce potassium iodate, and generating an iodine elementary substance to etch a gold nano bipyramid, so that the color of a solution is changed, and high-sensitivity detection on target miRNA is realized. The multi-color visual detection method provided by the invention is combined with the gold nano bipyramid localized surface plasmon resonance property change, so that near-full spectrum color change can be generated, and the portability of the sensor and the accuracy of visual analysis can be improved.

The invention provides application of linariin-6-O-glucoside in preparation of a product for preventing and treating osteoporosis, and relates to the field of biological medicine. According to the invention, dyeing experiments of alkaline phosphatase, alizarin red and tartaric acid resistant acid phosphatase prove that the sesaminin-6-O-glucoside has affinity for FPPS receptors, has the capability of promoting bone marrow mesenchymal stem cells to form bone cells, is superior to that of bisphosphate, and can inhibit the generation of osteoclasts; microCT (micro computed tomography) detection results show that the sesaminin-6-O-glucoside has the effect of relieving the osteoporosis and can promote the formation of bone trabecula. According to the application disclosed by the invention, it is proved for the first time that the sesaminin-6-O-glucoside has the effect of resisting osteoclast formation, and meanwhile, the sesaminin-6-O-glucoside also has a better osteogenesis effect, so that a basis is provided for developing the sesaminin-6-O-glucoside as a potential medicine for treating osteoporosis.

The present application relates to the technical field of biotechnology, and particularly relates to a D-dimer chemiluminescence assay kit. The present application provides a D-dimer chemiluminescence assay kit, which comprises a magnetic particle suspension (immunomagnetic beads) coated with D-dimer antibody 1, alkaline phosphatase-labeled D-dimer antibody 2 (enzyme-labeled antibody) and a calibrant. The immunomagnetic beads and the enzyme-labeled antibody are prepared by chemical coupling and stored in a buffer containing a soluble high molecular material, which can effectively improve the detection sensitivity and repeatability. The kit can be used in combination with a substrate solution containing a chromogenic substrate such as adamantane and its derivative AMPPD or APS-5 for a full-automatic immune test system, and the content of D-dimer in plasma or whole blood can be determined by a chemiluminescence instrument. The kit has high detection sensitivity and good repeatability.

Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).

The invention provides acellular matrix hydrogel loaded with animal acellular omentum particles as well as a preparation method and application of the acellular matrix hydrogel loaded with the animal acellular omentum particles, and relates to the technical field of tissue engineering and regenerative medicine. Comprising a decellularization treatment agent, a decellularization matrix, functional particles, an enzymolysis agent, a cross-linking stabilizer, a functional additive and a solvent, the functional additive is prepared from PDA coated Fe3O4 magnetic nano particles, phosphorylated polyglycerol sebacate and liposome coated silver nano particles. The PDA-Fe3O4 magnetic nanoparticles of the functional additive generate mechanical signals under the action of an external magnetic field, a Piezo1 mechanical gating cation channel is activated to promote calcium ion internal flow, and the autonomous mineralization ability of phosphorylated polyglycerol sebacate is combined, so that the activity of the bone differentiation marker alkaline phosphatase is effectively improved, and the bone differentiation marker alkaline phosphatase is prepared. The combination of the PDA coated Fe3O4 magnetic nanoparticles and the phosphorylated polyglycerol sebacate integrates a magnetic response mineralization system.

Bispecific antibody constructs comprising a first binding domain, which binds to human alkaline phosphatase, placental type (ALPP) and / or alkaline phosphatase, germ cell type (ALPPL2), on the surface of a tumor cell and a second binding domain, which binds to human CD3 on the surface of a T cell.

The invention provides a preparation method of an alpha-2, 3 sialic acid glycosyl transferase mediated sugar chain fixed-point coupling antibody drug conjugate, which comprises the following steps: S1, dissolving an antibody, adding UDP-Gal, Mn < 2 + > and beta-1, 4 galactosyl transferase for reaction, and purifying after reaction to obtain an antibody I with galactose at the tail end of a sugar chain; s2, dissolving the antibody I, adding an azide-modified CMP sialic acid derivative, alpha-2, 3 sialic acid glycosyltransferase and alkaline phosphatase for reaction, and purifying after reaction to obtain an antibody II of which the tail end of a carbohydrate chain is connected with the sialic acid derivative; s3, dissolving toxin molecules in DMSO, adding the dissolved toxin molecules into the antibody II for reaction, and performing ultrafiltration after the reaction to obtain ADC molecules; or the ADC molecule is directly prepared by adopting a one-pot enzyme method. The screened ST3Gal3 is used for preparing the carbohydrate chain fixed-point coupling ADC, the DAR value is controllable, batch-to-batch stability is achieved, uniformity is high, repeatability is high, quality control and CMC are better, and then the drug effect of the ADC can be better improved.

The invention discloses a preparation method of pichia pastoris expression secreting type deglycosylation alkaline phosphatase, and belongs to the technical field of biological engineering. According to the invention, the GS115-BIAP II pichia pastoris genetically engineered bacterium capable of secreting and expressing bovine intestine alkaline phosphatase BIAP II is prepared by using a conventional method. The method comprises the following steps: carrying out site-directed knockout on an ALG3 gene for coding alpha-1, 3-mannosyl transferase and an OCH1 gene for coding alpha-1, 6-mannosyl transferase by using a CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated Protein 9) technology to prepare a glycosylation gene defect type engineering bacterium GS115-delta ALG3-delta OCH1-BIAP II. The secretory expression BIAP II is deglycosylated alkaline phosphatase, and the specific activity of the secretory expression BIAP II is close to that of natural BIAP II. The deglycosylated alkaline phosphatase can improve the antibody coupling efficiency and marking uniformity under specific conditions. The method has remarkable advantages in chemiluminescence diagnosis, high-sensitivity immunodetection and development of multifunctional biological coupling reagents.

The invention relates to an anti-ovarian antibody chemiluminiscence kit and a preparation method thereof. The kit comprises amino magnetic beads coated with anti-ovarian antibody recombinant protein, anti-human immune globulin labeled by alkaline phosphatase, an anti-ovarian antibody calibrator and a chemiluminiscence substrate. The method has the beneficial effects that the 7-day acceleration stability of the AOAb coated amino magnetic bead is improved to 95% or above, the signal-to-noise ratio is high, the correlation coefficient is greater than 0.999, the test repeatability CV is less than 3.5%, the reagent correlation and the magnetic bead stability can be better improved, and the test result is ensured to be accurate. By optimizing the amino magnetic bead cross-linking agent, 60 clinical samples are tested and compared with the result of a comparison manufacturer, the total coincidence rate is as high as 98%, and false positive can be effectively reduced. Meanwhile, a detection system is formed by matching with a Guilin superior chemiluminescence immunoassay analyzer IA-260, the testing amount per hour reaches 130 tests, and compared with a traditional colloidal gold immunochromatography method and a traditional enzyme-linked immunosorbent assay method, the detection speed is greatly increased, and the result optimization accuracy is greatly improved.

This invention relates to the field of chemiluminescence detection technology for in vitro diagnostic reagents, specifically to an S100-β chemiluminescence detection kit and its preparation method. It provides a chemiluminescence detection kit for central nervous system-specific proteins using magnetic microparticles. The kit comprises: S100-β calibrator, S100-β monoclonal antibody conjugated with carboxyl magnetic beads, S100-β monoclonal antibody labeled with alkaline phosphatase, AMPPD chemiluminescence substrate solution acted upon by alkaline phosphatase, and concentrated washing buffer. This kit achieves the following: no sample pretreatment required, easy operation, high automation, high sensitivity, automatic result output in 16 minutes, good stability of calibrator and enzyme label, and low cost. It can meet the clinical needs for auxiliary diagnosis and treatment of acute ischemic brain injury.

Provided are a method for quantifying an amount of capped messenger RNA (mRNA) in an mRNA sample comprising contacting the mRNA with two or more of a nuclease, an alkaline phosphatase, and a polynucleotide kinase and separating the capped mRNA and the uncapped mRNA occurs using chromatography.

The present disclosure features methods for treating neutralizing antibodies that reduce the efficacy of soluble alkaline phosphatase therapy (e.g., asfoenzyme alpha), which is an enzyme replacement therapy, such as for the treatment of bone mineralization disorders, e.g., hypophosphoesterase (HPP). The methods include diagnosing the subject for the presence of a neutralizing antibody that affects the efficacy of the treatment, administering a treatment suitable for reducing the deleterious effects of the neutralizing antibody, and continuing an alkaline phosphatase treatment.

The invention provides a composite growth factor composition capable of promoting proliferation and osteogenic differentiation of bone marrow mesenchymal stem cells, a method and application. The invention provides the composite growth factor composition by simulating a natural secretion mode of a decalcified bone matrix of the mandible of an SD (Sprague Dawley) rat on the seventh day, the composite growth factor composition comprises BMP-2 (400-600 pg / ml), TGF-beta1 (5-7 ng / ml) and IGF-1 (150-250 ng / ml), and the optimal concentrations are 500 pg / ml, 6 ng / ml and 200 ng / ml respectively. The composition is remarkably superior to a single factor and a high-dosage combination in the aspects of promoting BMSCs proliferation, improving the activity of alkaline phosphatase (ALP) and forming mineralized nodules, meanwhile, the use dosage of growth factors is remarkably reduced, and the risk of side effects such as heterotopic ossification is reduced. The composite growth factor composition has good biocompatibility and safety, and is suitable for the fields of bone tissue engineering, bone defect repair and related regenerative medicine.

The application discloses a kind of self-assembly nanomaterial and its application in ROS clearance.The self-assembly nanomaterial of the application is denoted as TPP-FFYp-O, and its structural formula is shown as follows:TPP-FFYp-O of the application is specifically cut to generate TPP-FFY-O by alkaline phosphatase (ALP) overexpressed after entering inflammatory cell, TPP-FFY-O is enriched near mitochondrion by the targeting effect of TPP, and is self-assembled to form nanoparticle and stays in inflammatory cell by π-π stacking.Nanoparticle surface enrichment of a large number of TEMPO can convert superoxide radical anion (O2 ·‑ ) in mitochondrion into hydrogen peroxide (H2O2), and then decompose into oxygen and water, thereby significantly reducing the ROS level in inflammatory cell.This enzyme-controlled self-assembly nanoparticle improves the stability of TEMPO and the ability of ROS clearance, and has good application prospect.

The invention relates to an abnormal prothrombin detection kit. The kit comprises a first reagent, a second reagent and a third reagent. Wherein the first reagent comprises a buffer solution, a preservative and a blocking agent; the second reagent comprises a buffer solution, a stabilizer, a preservative, a sensitizer and alkaline phosphatase coupled with a PVKA-II monoclonal antibody; the third reagent comprises a buffer solution, a stabilizer, a preservative and carboxyl magnetic beads coupled with a PVKA-II monoclonal antibody. The kit disclosed by the invention has the advantages of good stability, strong specificity and the like, the detection result is more accurate, and clinical use is more facilitated.

The application discloses application of AML-12 exosomes in preparation of medicines for treating cholestatic liver injury, relates to the technical field of biological medicine, and discloses application of AML-12 cell-derived exosomes in preparation of medicines for preventing and treating ANIT-induced cholestatic liver injury; the treatment is manifested as reduction of alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase levels in serum. The application proves that the AML-12 cell-derived exosomes have a significant treatment effect on ANIT-induced cholestatic liver injury, successfully opens up the application of the biological preparation in a brand-new disease field, and fills the blank of the prior art; through in-vivo experiments, it is proved that AML-12 exosome treatment can significantly reduce liver cell injury markers and alkaline phosphatase, a key index of cholestasis, in serum of ANIT model mice, and improve pathological injury of liver tissue, thereby constituting a complete curative effect evidence chain from function to morphology.

The application discloses an enzyme response self-assembly polypeptide modified methacrylating polymer and a preparation method and application thereof, and the enzyme response self-assembly polypeptide modified methacrylating polymer has a structure of formula 1. The application converts an endogenous tissue-specific marker alkaline phosphatase concentration gradient into a dynamic gradient evolution of the mechanical properties of a scaffold. By introducing an enzyme response self-assembly polypeptide into a methacrylating polymer structure, the scaffold is subjected to molecular level dynamic self-assembly under the catalysis of phosphatase, and a continuous mechanical gradient is formed from a cartilage region to a subchondral bone region. The process does not require external intervention and is completely regulated by a local microenvironment, thereby real-time adapting to the dynamic requirements of 'early proliferation-late differentiation' of bone cartilage repair. Compared with the prior art, the application not only breaks through the mismatch between a static gradient and a dynamic microenvironment, but also precisely regulates mechanical signals at a molecular scale, and significantly improves the spatial specificity and time synchronism of stem cell differentiation.

The invention provides a cascade response self-assembly polypeptide for remodeling tumor cell antigen composition, a bioactive solution of the cascade response self-assembly polypeptide and application of the cascade response self-assembly polypeptide. The polypeptide sequentially comprises a hydrophobic end-capping group, an alkaline phosphatase response self-assembly polypeptide sequence, a reduced glutathione response sequence and a T cell epitope peptide sequence. The polypeptide can respond to high-expression alkaline phosphatase in a tumor microenvironment to generate self-assembly and promote efficient internalization of cells; then, the antigen peptide is released under the action of reductive glutathione in tumor cells, and the antigen complex is given to the tumor cells through a main histocompatibility complex I-type molecular antigen presentation pathway. In addition, the specific hydrophobic end-capping group can up-regulate expression of I-type molecules of main histocompatibility complexes of tumor cells, enhance antigen presentation and remarkably enhance the recognition and killing efficiency of antigen-specific T cells on the tumor cells. Combined adoptive immunity and immune checkpoint inhibitor therapy is suitable for combined immunotherapy of solid tumors.

The application discloses an active peptide for promoting bone growth, and a preparation method and application thereof. The active peptide contains amino acid sequences GPAGPLGPV, LGVPLPL, FLPEPPQEE and SFLPEPPQE, and is derived from an enzymatic product of animal bone collagen. The average molecular weight of the enzymatic product is 500-1000 Da, and the mass percentage of components with a molecular weight less than 1000 Da is greater than 60%. The preparation method comprises the following steps: sequentially performing acid treatment, alkali treatment, extraction, filtration and ion exchange on animal bone, and then performing enzymolysis on the animal bone under the action of a protease to obtain an enzymolysis solution, wherein the protease is selected from alkaline protease, trypsin and papain; and the enzymolysis solution is separated and purified, wherein the separation and purification comprises ultrafiltration membrane grading and chromatographic separation, the cut-off molecular weight of the ultrafiltration membrane is 3kDa, and the chromatographic separation comprises gel chromatography and reverse-phase high performance liquid chromatography separation. The low-molecular active peptide obtained by the application can promote the proliferation and / or differentiation of osteoblasts, improve the alkaline phosphatase activity, has a small molecular weight and is easy to be absorbed and utilized by the body, has a wide raw material source, has a simple and controllable preparation process, and has a good application prospect.

The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.

The present invention relates to the treatment of neurodegenerative diseases, a group of chronic progressive disorders characterized by the gradual loss of neurons or neuronal function in discrete regions of the central nervous system (CNS). In particular, the present invention relates to alkaline phosphatase (AP) for use in the treatment or prevention of mammals suffering from or at risk of neurodegenerative disorders caused by reduced peroxisome proliferator-activated receptor gamma coactivator 1 (PGC1) activity.

The invention discloses a fluorescent substrate 7-HC-P-E, a preparation method thereof and application of the fluorescent substrate 7-HC-P-E in detection of the active concentration of alkaline phosphatase (ALP). The fluorescent substrate can be catalytically hydrolyzed by ALP under an alkaline condition to release 7-hydroxycoumarin (7HC) with a strong fluorescent signal, so that high-sensitivity and high-specificity detection on the enzyme activity is realized. The invention further provides a synthesis route and an optimization process of the fluorescent substrate, the operation is simple and convenient, the product purity is high, and the fluorescent substrate is suitable for multiple fields such as biological analysis, medical diagnosis and environmental monitoring.

The invention discloses a Dam MTase and FEN1 dual-detection biosensor and a detection method. The detection method comprises the steps of recognition and cutting of a probe, release of two semi-activators, alkaline phosphatase treatment, synergistic activation of CRISPR-Cas12a and cutting of a substrate probe. According to the sensor, the activity of CRISPR-Cas12a is synergistically activated by using two semi-activators, so that the sensitivity and the specificity of detection are improved, and double detection of Dam MTase and FEN1 can be realized. Besides fluorescence detection, the sensor can also realize visual test strip detection. According to the detection method, nano material modification on the recognition probe is not needed, magnetic separation is not needed, and the detection cost is reduced. According to the detection method, all reactions are carried out in the same reaction tube, so that the operation process is simplified, and cross contamination possibly caused by multi-tube reaction operation is effectively avoided. The method can be applied to double detection of Dam MTase and FEN1 in a serum sample, so that the method has a wide application prospect in the fields of medical detection and the like.

The invention discloses a bionic delivery system and an anhydrous composition for enhancing hair follicle penetration. The system comprises a mesoporous nanocarbon core, a pH responsive charge reversal polymer layer, a bionic interface lipid regulation layer and at least two loaded oligopeptide precursor molecules. The polymer layer is protonized and positively charged in a scalp microenvironment, so that a hair follicle opening is accurately anchored; the lipid regulation layer temporarily enhances the lipid fluidity of hair follicles in a non-invasive manner and promotes the permeation of active matters; the oligopeptide precursor is triggered by alkaline phosphatase in the deep part of the hair follicle and is self-assembled into the active target oligopeptide through in-situ biological orthogonal connection. A composition comprises the nanosystem, a natural deep eutectic solvent, a plant source emollient and a zinc salt complex, and synergistically enhances permeation and release. The system realizes accurate, efficient and safe delivery of active matters in the deep part of hair follicles, and is suitable for prevention and treatment of hair follicle related diseases.

The invention relates to the field of instant detection of disease diagnosis, and discloses an Alzheimer's disease marker detection method based on enzymatic fluorescent silicon nanodots, which comprises the following steps: enriching a target marker by using a magnetic capture probe and forming an enzyme-labeled immune sandwich compound; adding a substrate, and performing in-situ induction by using ascorbic acid generated by enzymatic reaction to generate fluorescent silicon nanodots or inhibit chromogenic reaction; the method comprises the following steps: acquiring a time sequence image of a reaction system, eliminating interference pixels by utilizing HSV color space conversion and a chromaticity characteristic mask algorithm, calculating a reaction kinetics rate, and combining a standard curve to realize quantitative analysis. By introducing an alkaline phosphatase-induced cascade reaction system and utilizing an enzymolysis product ascorbic acid to generate fluorescent silicon nanodots in situ or regulate and control the oxidation-reduction state of TMB (Tetramethylbenzidine), high-sensitivity detection of Tau protein and Abeta-42 protein is realized, so that the detection sensitivity of low-concentration Alzheimer's disease markers is improved.

The invention discloses a small molecule peptide with cytotoxicity to breast cancer cells and application, and relates to the technical field of establishment and preparation of a small molecule peptide nano-drug delivery system. The small molecule peptide is a targeted peptide modified alkaline phosphatase reaction peptide, responds to ALP enzyme, is specifically combined with an integrin receptor, is self-assembled into spherical nanoparticles and serves as a nano drug carrier, and the structural formula is shown in figure 1. The research successfully designs and synthesizes a small molecule peptide with cytotoxicity to breast cancer cells, the small molecule peptide can be self-assembled into a nano NP drug delivery system, and an in-vitro experiment result shows that the self-assembled nano NP drug delivery system can quickly release chemotherapeutic drugs in an ALP overexpression environment, has small damage to healthy cells, is relatively low in cytotoxicity, and can be used for preparing a chemotherapeutic drug for treating breast cancer. However, the damage to cancer cells is obvious, and the action time of the medicine can be prolonged. An in-vivo anti-tumor experiment shows that compared with a non-deformable control peptide, the small molecule peptide drug loading system has a remarkable anti-tumor effect.

The invention provides a polypeptide derivative, a polypeptide hydrogel bone in-situ generation method and application. The polypeptide derivative is Npx-fFfFpYGPO (N, N-dimethyl formamide). In the invention, a solution of the polypeptide derivative can be directly injected into a bone injury lacuna, and is decatalyzed by high-expression alkaline phosphatase at an injury part to form hydrogel in situ. The collagen-like polypeptide hydrogel can provide a support for adhesion and proliferation of cells, can accelerate calcium precipitation by providing fluorine signals and phosphate radicals, has the effects of resisting inflammation and regulating and controlling polarization of macrophages, and provides a good microenvironment for bone tissue regeneration. The polypeptide derivative can be perfectly attached to various irregular bone injury parts due to the in-situ gelation performance of the polypeptide derivative, invalid cavities are reduced, and the polypeptide derivative is simple to prepare, low in cost and controllable in component and has a good application prospect.

The invention relates to the technical field of immunoassay, and discloses a chemiluminescence immunoassay method for high-sensitivity detection of cardiac troponin I. The chemiluminescence immunoassay method comprises the following steps: fixing an anti-cardiac troponin I capture antibody based on a solid phase carrier; a sample to be detected is in contact with the solid phase carrier coated with the capture antibody, a detection antibody is added, the detection antibody is connected with a signal marker, and the signal marker is a compound formed by loading alkaline phosphatase on a nano material or is the nano material; a chemiluminescent substrate is added, and the chemiluminescent substrate is a compound based on 1, 2-dioxetane; detecting a chemiluminescence signal so as to quantify cardiac troponin I; according to the invention, the problem of non-uniform detection of degradation fragments is solved, and the diagnosis window period is prolonged; meanwhile, extremely high detection sensitivity, signal-to-noise ratio and stability are realized, and the kit is suitable for early and accurate diagnosis of myocardial injury.